Eli Lilly and Company (NYSE:LLY) Shares Sold by Aviva PLC

Aviva PLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.7% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 494,111 shares of the company’s stock after selling 18,921 shares during the quarter. Eli Lilly and Company makes up approximately 1.0% of Aviva PLC’s holdings, making the stock its 13th largest holding. Aviva PLC’s holdings in Eli Lilly and Company were worth $381,454,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Principal Financial Group Inc. grew its position in Eli Lilly and Company by 5.3% during the 3rd quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after purchasing an additional 60,306 shares during the last quarter. Point72 Asset Management L.P. acquired a new stake in shares of Eli Lilly and Company during the third quarter worth $11,657,000. Temasek Holdings Private Ltd grew its holdings in shares of Eli Lilly and Company by 132.1% during the third quarter. Temasek Holdings Private Ltd now owns 70,300 shares of the company’s stock valued at $62,282,000 after buying an additional 40,017 shares during the last quarter. Weaver Consulting Group increased its position in shares of Eli Lilly and Company by 7.4% in the 3rd quarter. Weaver Consulting Group now owns 635 shares of the company’s stock valued at $563,000 after acquiring an additional 44 shares during the period. Finally, Wallace Capital Management Inc. raised its stake in Eli Lilly and Company by 9.7% in the 3rd quarter. Wallace Capital Management Inc. now owns 1,130 shares of the company’s stock worth $1,001,000 after acquiring an additional 100 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.13% of the stock is currently owned by corporate insiders.

Eli Lilly and Company Trading Down 6.5 %

Shares of LLY stock opened at $737.56 on Friday. Eli Lilly and Company has a 1-year low of $711.40 and a 1-year high of $972.53. The company has a market cap of $699.33 billion, a price-to-earnings ratio of 62.99, a PEG ratio of 1.40 and a beta of 0.34. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97. The stock has a 50 day simple moving average of $848.36 and a 200-day simple moving average of $832.44.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. On average, equities research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company declared that its board has approved a stock buyback plan on Monday, December 9th that permits the company to repurchase $15.00 billion in shares. This repurchase authorization permits the company to purchase up to 2% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its shares are undervalued.

Wall Street Analysts Forecast Growth

LLY has been the topic of several research analyst reports. Leerink Partners set a $950.00 price target on Eli Lilly and Company in a research note on Friday, January 17th. Citigroup cut their price target on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a report on Tuesday, January 28th. Morgan Stanley set a $1,146.00 price target on shares of Eli Lilly and Company in a research report on Thursday, March 6th. Bank of America reaffirmed a “buy” rating and issued a $997.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Finally, Wells Fargo & Company raised their target price on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Three research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company currently has an average rating of “Moderate Buy” and a consensus target price of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.